Patient Perspectives on an Optimal Outcome Measure to Assess Efficacy in the Acute Treatment of Hereditary Angioedema AttacksRiedl MA, Cohn DM, Aygören-Pürsün E, Zanichelli A, Farkas H, Bernstein JA, Lumry WR, Smith MD, Yea CM, Audhya PK
2022 HAEi Global Leadership Workshop
Pharmacology of KVD824, an Investigational Drug for Prophylaxis of HAEGrivcheva-Panovska V, Smith MD, Duckworth EJ, Hampton SL, Yea CM, Mutch P, Iverson M, Hansen E, Feener EP
BRADYKININ SYMPOSIUM
Sebetralstat Effectiveness in the Treatment of Hereditary Angioedema Attacks Rated Mild or Moderate at Baseline in the Phase 2 TrialLonghurst HJ, Smith MD, Yea CM, Audhya PK
ASCIA 2022
Efficacy and Safety of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) in Adolescent and Adult Patients With Hereditary Angioedema: Phase 3 Trial DesignAygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Bernstein JA , Audhya PK, Smith MD, Yea CM, Lumry WR, Riedl MA, Maurer M
EAACI 2022
Novel Oral Small Molecule FXIIa Inhibitor Blocks Contact System Activation In VivoAllen C Clermont, Daniel Lee, Nivetha Murugesan, Hannah J Edwards, Stephen J Pethen, Edward J Duckworth, Sally L Hampton and Edward P Feener
EAACI 2022
Population Pharmacokinetic Analysis of Sebetralstat (KVD900) in Healthy Adult Volunteers and Patients With Hereditary Angioedema Predicts Similar Exposure in Adolescent PatientsSmith MD, Rodgers T, Sharman J, Mutch P, Tachdjian R, Savic S, Farrell C
EAACI 2022
Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients With Hereditary AngioedemaAygören-Pürsün E, Zanichelli A, Cohn DM, Audhya PK, Williams P, Yea CM, Smith MD
EAACI 2022
Oral factor XIIa inhibition blocks angiotensin converting enzyme inhibitor induced angioedema in mouseClermont AC, Murugesan N, Feener EP
KININ 2022
Oral FXIIa inhibitor KV998086 suppresses FXII zymogen mediated kallikrein kinin system activationMurugesan N, Lee DK, Duckworth EJ, Smith SA, Clermont AC, Hampton SL, Feener EP
KININ 2022
Oral sebetralstat (KVD900) provides rapid inhibition of the kallikrein kinin system in patients with hereditary angioedemaDuckworth EJ, Lee DK, Murugesan N, Rushbrooke L, Hampton SL, Smith M, Yea C, Audhya P, Feener EP
KININ 2022